Stemagen is a company dedicated to the goal of hastening the day stem cells are used routinely to treat these devastating diseases. To accomplish this we are developing proprietary methods for deriving, maintaining and optimizing human embryonic stem cell lines, ones that can be used for cell-based therapeutics to treat a variety of degenerative diseases. - (Read more)

Epistem are epithelial stem cell and tissue experts, delivering innovative preclinical contract research services in the areas of oncology, mucositis, biomarker identification, inflammatory bowel disease, wound healing and skincare. Epistem has developed a range of unique models for target validation, in vitro screening, early assessment of epithelial toxicity, in vivo efficacy and translational biology. As the Company continues to expand its service portfolio, in vitro and in vivo angiogenesis models, an in vitro cancer stem cell assay and proprietary hair follicle biomarker platform have recently been introduced. Working with over 90 pharmaceutical, biotechnology, and personal care companies worldwide, we assist with various stages of the drug discovery and development process. - (Read more)

Cloned Human Embryo Created From Skin Cells

ScienceDaily (Jan. 22, 2008) — Stemagen, a privately held embryonic stem cell research company, announced January 17 it has become the first in the world to create, and meticulously document, a cloned human embryo using somatic cell nuclear transfer (SCNT).

[Read more]